Remove Diabetes Remove Kidney Disease Remove Outpatient
article thumbnail

Abstract WP278: Trends in GLP1RA and SGLT2i Use in Ischemic Stroke Patients With Diabetes

Stroke Journal

Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE. Patients were identified to have diabetes as derived by the Charlson Comorbidity Index ICD 10 codes E10 through E14.

article thumbnail

Multispecialty multidisciplinary input into comorbidities along with treatment optimisation in heart failure reduces hospitalisation and clinic attendance

Open Heart

Outcome measures were (1) all-cause hospitalisations, (2) outpatient clinic attendances and (3) cost. Multispecialty interventions included optimising diabetes therapy (haemoglobin A1c-HbA1c pre-MDT 68±11 mmol/mol vs post-MDT 61±9 mmol/mol; p<0.001), deprescribing to reduce anticholinergic burden (pre-MDT 1.85±0.4

article thumbnail

Advance in the Treatment of Acute Heart Failure Identified

DAIC

The drug, dapagliflozin, was initially approved for the treatment of Type 2 diabetes, but it since has been shown to reduce the risk of hospitalization for heart failure and death in patients with serious health problems that include heart and chronic kidney disease and heightened cardiovascular risk.

article thumbnail

Risk factors, outcomes and healthcare utilisation in individuals with multimorbidity including heart failure, chronic kidney disease and type 2 diabetes mellitus: a national electronic health record study

Open Heart

Background Heart failure (HF), type 2 diabetes (T2D) and chronic kidney disease (CKD) commonly coexist. In multivariable analyses, we identified risk factors for developing the third condition and mortality, such as age, sex, medical history and the order of disease diagnosis.

article thumbnail

SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”

article thumbnail

EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”

article thumbnail

Abstract 280: Risk Factors in 90day Ischemic Stroke Readmissions

Stroke: Vascular and Interventional Neurology

In multivariate regression analysis, the factors independently associated with a greater risk of readmission within 90 days were hypercoagulation (1.359 [95%CI, 1.1274‐1.45]), opiod abuse and dependence (1.353 [95%CI, 1.238‐1.478]), chronic kidney disease (1.347 [95%CI, 1.316‐1.379]), liver disease (1.318 [95% CI, 1.26‐1.378]),